Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Bomgaars

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemiaSima Jeha, Bassem Razzouk, Michael Rytting, et al.
Journal of Thrombosis and Haemostasis : JTH|February 26, 2021
Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolismDaniel Röshammar, Fenglei Huang, Manuela Albisetti, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolismManuela Albisetti, Branislav Biss, Lisa Bomgaars, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and designMatteo Luciani, Manuela Albisetti, Branislav Biss, et al.
Blood|December 6, 2019
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in childrenLeonardo R Brandão, Manuela Albisetti, Jacqueline Halton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2016
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move ForwardJoanne P Lagmay, Mark D Krailo, Ha Dang, et al.
The Lancet. Haematology|December 8, 2020
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trialJacqueline Halton, Leonardo R Brandão, Matteo Luciani, et al.
The New England Journal of Medicine|August 10, 2012
Prospective trial of a pediatric ventricular assist deviceCharles D Fraser, Robert D B Jaquiss, David N Rosenthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2018
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology GroupDouglas S Hawkins, Yueh-Yun Chi, James R Anderson, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemiaSima Jeha, Bassem Razzouk, Michael Rytting, et al.
Journal of Thrombosis and Haemostasis : JTH|February 26, 2021
Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolismDaniel Röshammar, Fenglei Huang, Manuela Albisetti, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolismManuela Albisetti, Branislav Biss, Lisa Bomgaars, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and designMatteo Luciani, Manuela Albisetti, Branislav Biss, et al.
Blood|December 6, 2019
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in childrenLeonardo R Brandão, Manuela Albisetti, Jacqueline Halton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2016
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move ForwardJoanne P Lagmay, Mark D Krailo, Ha Dang, et al.
The Lancet. Haematology|December 8, 2020
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trialJacqueline Halton, Leonardo R Brandão, Matteo Luciani, et al.
The New England Journal of Medicine|August 10, 2012
Prospective trial of a pediatric ventricular assist deviceCharles D Fraser, Robert D B Jaquiss, David N Rosenthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2018
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology GroupDouglas S Hawkins, Yueh-Yun Chi, James R Anderson, et al.
Pageof 3